Hypercalcaemia, Parathyroid Hormone-Related Protein and Malignancy

Bayne, Mike; Illidge, T.

doi:10.1053/clon.2001.9293

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTHrP and parathyroid hormone (PTH) share the same cell surface receptor, PTH/PTHrP receptor or PTHR (Vilardaga et al, 2011). While PTH secreting tumors are very rare, secondary hyperparathyroidism is frequently observed among CKD patients (Bayne and Illidge, 2001; Levin et al, 2007; Tentori et al, 2015). Here, using fat-specific PTHR-deficient mice, we investigated the role of the adipose PTH/PTHrP pathway in cachexia associated with both CKD and cancer.…”

Section: Introductionmentioning

confidence: 99%

PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer

et al. 2016

View full text Add to dashboard Cite

SUMMARY Cachexia is a wasting syndrome associated with elevated basal energy expenditure and loss of adipose and muscle tissues. It accompanies many chronic diseases including renal failure and cancer and is an important risk factor for mortality. Our recent work demonstrated that tumor-derived PTHrP drives adipose tissue browning and cachexia. Here, we show that PTH is involved in stimulating a thermogenic gene program in 5/6 nephrectomized mice that suffer from cachexia. Fat-specific knockout of PTHR blocked adipose browning and wasting. Surprisingly, loss of PTHR in fat tissue also preserved muscle mass and improved muscle strength. Similarly, PTHR knockout mice were resistant to cachexia driven by tumors. Our results demonstrate that PTHrP and PTH mediate wasting through a common mechanism involving PTHR and there exists an unexpected crosstalk mechanism between wasting of fat tissue and skeletal muscle. Targeting the PTH/PTHrP pathway may have therapeutic uses in humans with cachexia.

show abstract

Section: Introductionmentioning

confidence: 99%

PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

A systematic review of the role of bisphosphonates in metastatic disease

Ross

Saunders²,

Edmonds³

et al. 2004

Health Technol Assess

258

110

View full text Add to dashboard Cite

High dose aminobisphosphonates are most effective for the treatment of acute hypercalcaemia and delay time to relapse. Bisphosphonates significantly reduce SREs and delay the time to first SRE in patients with bony metastatic disease but do not affect survival. Benefit is demonstrated after administration for at least 6-12 months. The greatest body of evidence supports the use of intravenous aminobisphosphonates. Further evidence is required to support use in the adjuvant setting.

show abstract